Skip to main content
. 2021 Aug 6;13(8):1214. doi: 10.3390/pharmaceutics13081214

Figure 9.

Figure 9

Fluorescence imaging study by IVIS Lumina XRMS. (a) Imaging of U87-MG xenograft model at 30 min, 1 h, 4 h, 8 h, and 24 h post-injection of TSPO-targeted NP of 200 µg. (b) Inhibition study using PK 11195 (10 mg/1 kg). (c) Tumor-to-skin ratios in mouse models with PK 11195 pre-injection or without PK11195 pre-injection. Reproduced with permission [38]. Copyright © 2021 Elsevier B.V. All rights reserved.